Claims for Patent: 12,252,494

Summary for Patent: 12,252,494

Title:	Dosing regimens of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine for treatment of indolent systemic mastocytosis
Abstract:	Crystalline Forms of Compound (I): pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.
Inventor(s):	Brenton Mar, Anthony L. Boral, Hui-Min Lin, Hongliang Shi
Assignee:	Blueprint Medicines Corp
Application Number:	US18/077,431
Patent Claims:	1. A method of treating a patient with indolent systemic mastocytosis (ISM) comprising administering to the patient 25 mg of Compound (I) once daily: or administering to the patient a pharmaceutically acceptable salt of Compound (I) in an amount equivalent to 25 mg of Compound (I) once daily. 2. The method of claim 1, wherein the patient has a mutation in Exon 17 in KIT. 3. The method of claim 2, wherein the patient has a D816 mutation in KIT in Exon 17. 4. The method of claim 3, wherein the D816 mutation is D816V. 5. The method of claim 1, wherein the patient has a minimum total symptom score (TSS) of >28 as assessed using the indolent systemic mastocytosis-symptom assessment form (ISM-SAF). 6. The method of claim 1, further comprising administering an effective amount of an antihistamine. 7. The method of claim 1, wherein 25 mg of Compound (I): is administered to the patient once daily.